Placebo + Dalteparin
Phase 2Completed 2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Trial Timeline
May 1, 2011 → Jul 1, 2014
NCT ID
NCT01419977About Placebo + Dalteparin
Placebo + Dalteparin is a phase 2 stage product being developed by Eisai for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01419977. Target conditions include Sickle Cell Disease, Vaso-occlusive Crisis.
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease were approved
Approved (3) Terminated (10) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01419977 | Phase 2 | Completed |
Competing Products
20 competing products in Sickle Cell Disease